Antimalarial activities and therapeutic properties of febrifugine analogs.
Febrifugine is the active principal isolated 50 years ago from the Chinese herb chang shan (Dichroa febrifuga Lour), which has been used as an antimalarial in Chinese traditional medicine for more than 2,000 years. However, intensive study of the properties of febrifugine has been hindered for decades due to its side effects. We report new findings on the effects of febrifugine analogs compared with those of febrifugine extracted from the dry roots of D. febrifuga. The properties of the extracted febrifugine were comparable to those obtained from the standard febrifugine provided by our collaborators. A febrifugine structure-based computer search of the Walter Reed Chemical Information System identified 10 analogs that inhibited parasite growth in vitro, with 50% inhibitory concentrations ranging from 0.141 to 290 ng/ml. The host macrophages (J744 cells) were 50 to 100 times less sensitive to the febrifugine analogs than the parasites. Neuronal (NG108) cells were even more insensitive to these drugs (selectivity indices, >1,000), indicating that a feasible therapeutic index for humans could be established. The analogs, particularly halofuginone, notably reduced parasitemias to undetectable levels and displayed curative effects in Plasmodium berghei-infected mice. Recrudescence of the parasites after treatment with the febrifugine analogs was the key factor that caused the death of most of the mice in groups receiving an effective dose. Subcutaneous treatments with the analogs did not cause irritation of the gastrointestinal tract when the animals were treated with doses within the antimalarial dose range. In summary, these analogs appear to be promising lead antimalarial compounds that require intensive study for optimization for further down-selection and development.
Jiang
Suping
S
Department of Parasitology, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA. suping.jiang@na.amedd.army.mil
Zeng
Qiang
Q
Gettayacamin
Montip
M
Tungtaeng
Anchalee
A
Wannaying
Srisombat
S
Lim
Apassorn
A
Hansukjariya
Pranee
P
Okunji
Christopher O
CO
Zhu
Shuren
S
Fang
Daohe
D
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology* / Q000627:therapeutic use; D002460:Cell Line; D008264:Macrophages / Q000187:drug effects; D051379:Mice; D008813:Mice, Inbred ICR; D010880:Piperidines; D011799:Quinazolines / Q000494:pharmacology*
D000962:Antimalarials; D010880:Piperidines; D011799:Quinazolines; C001207:febrifugine
Antimicrob Agents Chemother. 1979 Dec;16(6):710-8
394674
Biochem Pharmacol. 1999 Nov 15;58(10):1593-601
10535750
J Med Chem. 1970 Sep;13(5):867-70
5458373
J Parasitol. 1983 Jun;69(3):577-83
6355423
Biochem Pharmacol. 1996 Oct 11;52(7):1057-63
8831725
Gen Pharmacol. 1998 Apr;30(4):445-50
9522159
J Am Chem Soc. 1949 Mar;71(3):1048-54
18124517
J Am Chem Soc. 1947 Jul;69(7):1837
20251439
J Med Chem. 2002 Jun 6;45(12):2563-70
12036365
Nature. 1948 Mar 13;161(4089):400
18916817
Science. 1999 Sep 3;285(5433):1502-3
10498534
J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
2359136
J Am Chem Soc. 1948 Jun;70(6):2091-3
18863804
Science. 1976 Aug 20;193(4254):673-5
781840
Adv Pharmacol Chemother. 1973;11:221-93
4591806
Antimicrob Agents Chemother. 2001 Sep;45(9):2577-84
11502532
J Hepatol. 1997 Aug;27(2):391-8
9288615
Heart Vessels. 1998;13(1):18-23
9923561
Pharmacol Ther. 2001 Feb;89(2):207-19
11316521
Science. 1946 Jan 11;103(2663):59
17835430
Neoplasia. 1999 Oct;1(4):321-9
10935487
Connect Tissue Res. 1996;34(2):97-103
8909874
J Med Chem. 2003 Sep 25;46(20):4351-9
13678413
J Med Chem. 1999 Aug 12;42(16):3163-6
10447961
J Nat Prod. 1998 Jun 26;61(6):729-33
9644055
Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):1082-6
8887611